Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT04855526

THC + CBD and Memory Study

Memory deficits are one of the most consistently observed cognitive effects of marijuana use. There is evidence that some decrements attributable to the primary psychoactive ingredient, delta-9-tetrahydrocannabinol (THC), may be attenuated by cannabidiol (CBD). This study will help us learn more about the relationship between THC and CBD consumption with memory processes. A combination of MRI and neuropsychological tests (which are computer and paper/pencil tasks) will be used to measure the neurocognitive and behavioral impacts of THC and CBD use.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

18 year–40 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Early Phase 1

About this study

With increased legalization and medicalization of marijuana (MJ), there is an urgent need to understand the acute effects of use. One of the most consistently observed cognitive outcomes associated with MJ use is memory dysfunction, which may have a substantial impact on daily life in individuals using MJ for recreational or medicinal purposes. Notably, there are numerous preparations of MJ with varying proportions of cannabinoids, which may differ in behavioral and cognitive effects. For instance, there is emerging evidence that acute administration of delta-9-tetrahydrocannabinol (THC), the main psychoactive constituent of MJ, hinders memory and reduces prefrontal and hippocampal functional magnetic resonance imaging (fMRI) activation, but cannabidiol (CBD) may mitigate some of these impairments. Given the role of glutamate in learning and memory, the investigators suggest that these effects may be subserved, in part, by glutamatergic mechanisms. The investigators will use magnetic resonance spectroscopy (MRS) to non-invasively measure glutamate in order to explore the neurochemical underpinnings of memory-related fMRI response changes following acute administration of THC and CBD in a randomized, double-blind, placebo-controlled, cross-over design. A total of 9 healthy participants ages 18-40 will be enrolled. Participants will first undergo one screening visit (~4 hours), comprising informed consent, assessment of health history, psychiatric diagnoses, cognitive function, and substance use history, and a structural MRI session. This will be followed by 3 separate MJ dose visits (~4 hours each), at which participants will complete neuroimaging after administration of one of 3 preparations of vaporized MJ in a randomized, counterbalanced, double-blinded fashion: 1) high THC and no CBD (THC), 2) high THC and high CBD (THC+CBD), and 3) no THC and no CBD (placebo MJ). As in the investigator's ongoing studies, bulk MJ plant material will be provided by the National Institute on Drug Abuse. MJ dose visits will comprise MJ administration, blood collection, MRS/fMRI scan, subjective reports, and a brief cognitive assessment.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Right-handed
  • Prior MJ users (has used MJ at least once in the past year, but no more than 1x/month in the past 12 months)
  • Medically healthy (as determined by medical history and treatment)
  • Adequate comprehension of English in order to complete study materials
  • Acceptable birth control method for women (i.e., no copper IUD or any device that is not MRI safe)

Exclusion criteria

  • Participant currently uses psychoactive medications or substances
  • Psychiatric diagnoses (determined by DSM-V)
  • Participant heavily or regularly uses MJ (more than 1x/month in the past year)
  • Current or past substance dependence (including MJ)
  • Positive urine toxicology screens
  • Positive pregnancy screens
  • MRI contraindications (e.g., heart pacemaker)

Treatment and study plan

High THC/No CBD Marihuana

Drug

high THC (65 mg THC) and no CBD (0 mg CBD)

High THC/High CBD Marihuana

Drug

high THC (65 mg THC) and high CBD (50 mg CBD)

No THC/No CBD Marihuana

Drug

no THC (0 mg THC) and no CBD (0 mg CBD); placebo drug

Primary outcomes

  1. fMRI response

    Time frame: approximately 1 hour following drug administration

    Blood oxygen level dependent functional magnetic resonance imaging (fMRI) response during the relational and item specific encoding task. fMRI response will be evaluated during the encoding phase (relational vs. item encoding), item recognition phase (hits vs. misses for item-specific encoding, and hits vs. misses for relational encoding), and associative recognition phase (hits vs. misses).

  2. Glutamate

    Time frame: approximately 1 hour following drug administration

    Magnetic resonance spectroscopy (MRS)-acquired glutamate containing compounds (Glx).

Secondary outcomes

  1. HVLT-R performance

    Time frame: Approximately 2.50 hours after drug administration

    The Hopkins Verbal Learning Test-Revised will ascertain verbal list learning and immediate and delayed recall (~15min); alternate forms have been validated, and the order of versions participants receive will be randomized

  2. Performance on CHARLIE cognitive task

    Time frame: Approximately 3.00 hours after drug administration

    This is a computer-based cognitive battery that administers the Digit Span and Letter/Number Sequencing Test (working memory) and the Digit Symbol Coding test (processing speed). It should take about 10 minutes to complete.

  3. Blood THC and CBD concentration testing

    Time frame: Immediately after drug administration (~0.25 hours after drug administration)

    A blood sample will be taken once per dose visit to assess the concentration of the following metabolites in ng/mL: delta-9-tetrahydrocannabinol, 11-hydroxy-tetrahydrocannabinol, 11-Nor-9-Carboxy-tetrahydrocannabinol (THCCOOH), tetrahydrocannabinol-Glucuronide, THCCOOH-Glucuronide, cannabinol (CBN), and cannabidiol (CBD).

  4. Subjective effects on drug effects questionnaire

    Time frame: Post drug administration at: 0.00 hours (immediately after); 1.0 hours; 2.0 hours; 3.0 hours

    This self-report will be used to assess subjective reports every 60 minutes throughout the dose visit days. These subjective ratings will be obtained using rapidly completed Visual Analog Scales (VASs) scored on a 0-100 scale. Items include: Do you feel a drug effect right now?, Are you high right now?, Do you dislike any of the effects you are feeling right now?, Do you like any of the effects you are feeling right now? and Would you like more of the drug you took, right now?

Study contacts

Contact information is provided by the study sponsor or research team.

Chelsea N Meagher, BA

CONTACT

[email protected]

860-545-7106

Diana G King, BA

CONTACT

[email protected]

860-545-7563

Sponsors and collaborators

Lead sponsor

Hartford Hospital

Other

Collaborators

  • Yale University

Registry information

Official study title

Effects of Marijuana on Memory-Related Neurochemistry and Neural Response

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
Apr 22, 2021
Registry last updated
Mar 17, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.